LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Akciju saraksts・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Slēgts

SektorsVeselības aprūpe

25.93 4.05

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

24.21

Max

27.03

Galvenie mērījumi
By Trading Economics
Ienākumi	51M -129M
Pārdošana	207M
Peļņas marža	-62.319
Darbinieki	1,371
EBITDA	8.8M -105M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+111.85% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	460M 2.4B
Iepriekšējā atvēršanas cena	21.88
Iepriekšējā slēgšanas cena	25.93

Ziņu noskaņojums

By Acuity

40%

60%

154 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

32.76 / 39.24 Atbalsts un pretestība

Ultragenyx Pharmaceutical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. maijs 23:41 UTC

Peļņas

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

2026. g. 6. maijs 21:40 UTC

Peļņas

Nutrien Logs Higher Profit, Sales Growth in 1Q

2026. g. 6. maijs 23:47 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026. g. 6. maijs 23:34 UTC

Tirgus saruna

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

2026. g. 6. maijs 23:13 UTC

Peļņas

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 6. maijs 23:13 UTC

Peļņas

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

2026. g. 6. maijs 23:12 UTC

Peļņas

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

2026. g. 6. maijs 23:11 UTC

Peļņas

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

2026. g. 6. maijs 23:11 UTC

Peļņas

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

2026. g. 6. maijs 23:11 UTC

Peļņas

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

2026. g. 6. maijs 23:11 UTC

Peļņas

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

2026. g. 6. maijs 23:11 UTC

Peļņas

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

2026. g. 6. maijs 23:11 UTC

Peļņas

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

2026. g. 6. maijs 23:07 UTC

Peļņas

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

2026. g. 6. maijs 23:06 UTC

Peļņas

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

2026. g. 6. maijs 23:06 UTC

Peļņas

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

2026. g. 6. maijs 23:05 UTC

Peļņas

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

2026. g. 6. maijs 23:04 UTC

Peļņas

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

2026. g. 6. maijs 22:50 UTC

Peļņas

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026. g. 6. maijs 22:25 UTC

Tirgus saruna

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

2026. g. 6. maijs 22:11 UTC

Peļņas

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

2026. g. 6. maijs 22:11 UTC

Peļņas

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

2026. g. 6. maijs 22:05 UTC

Tirgus saruna

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

2026. g. 6. maijs 21:58 UTC

Peļņas

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026. g. 6. maijs 21:47 UTC

Tirgus saruna

Peļņas

Costco Posts 13% Sales Growth in April -- Market Talk

2026. g. 6. maijs 21:46 UTC

Peļņas

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

2026. g. 6. maijs 21:40 UTC

Peļņas

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026. g. 6. maijs 21:35 UTC

Tirgus saruna

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

2026. g. 6. maijs 21:32 UTC

Karstas akcijas

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

2026. g. 6. maijs 21:29 UTC

Peļņas

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Ultragenyx Pharmaceutical Inc Prognoze

Cenas mērķis

By TipRanks

111.85% augšup

Prognoze 12 mēnešiem

Vidējais 52.56 USD 111.85%

Augstākais 84 USD

Zemākais 25 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ultragenyx Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ultragenyx Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

32.76 / 39.24Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Noskaņojums

By Acuity

154 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.